VEGF seems to play an important role in the pathogenesis of keloids and may be a useful guide in the evaluation of keloid therapeutics. Modulation of its production may provide a valuable treatment for keloids.
BACKGROUNDNail psoriasis has a major negative impact on physical and psychological aspects of the patient's life. Treatment is often unsatisfactory because of difficult penetration of the drug into the nail.OBJECTIVETo evaluate and compare the efficacy of laser-assisted delivery of methotrexate versus its intralesional injection in fingernail psoriasis.MATERIALS AND METHODSTwenty-eight patients with fingernail psoriasis were divided into 2 groups of 14 patients each. Group A was treated with intralesional injection of methotrexate while Group B received fractional CO2 laser followed by topical application of methotrexate. The treatment was given at a 2-week interval for 6 sessions. The improvement of nail psoriasis was assessed by clinical and dermoscopic evaluation.RESULTSAt the end of treatment, both laser-assisted delivery and intralesional injection of methotrexate were associated with statistically significant improvement of psoriatic signs. No statistically significant difference was found between the 2 groups regarding total nail psoriasis severity Index (p = .18), matrix score (p = .38), bed score (p = .23), and dermoscopic score (p = .78). However, the pain and subungual hematoma were significantly less in the laser group (p < .001 and p = .03, respectively).CONCLUSIONFractional CO2 laser-assisted delivery of methotrexate can be an effective and well-tolerated alternative to intralesional injection in nail psoriasis.
Background and objectives: The treatment of nail psoriasis is often unsatisfactory due to poor penetration of topical therapeutics through the nail plate. The development of innovative methods that provide adequate delivery of the drug into the nail is warranted. In this study, we aim to compare the efficacy of intralesional corticosteroid injection versus its topical application after fractional CO 2 laser in the treatment of fingernail psoriasis. Patients and Methods:The study included 36 patients with fingernail psoriasis divided into two groups. The nails in group A were treated with intralesional injection of triamcinolone acetonide while the nails in group B received fractional CO 2 laser therapy followed by topical application of the drug for six sessions. The evaluation was performed using NAPSI and dermatoscopic scores.Results: Both modalities yielded a significant improvement of the nail matrix and bed psoriatic signs. No statistically significant difference was found between the two groups by both clinical and dermatoscopic assessment. The laser treatment was associated with significantly lower pain scores (P = 0.03) and higher patient satisfaction (P = 0.007). Conclusions:Fractional CO 2 laser-assisted delivery of topical corticosteroids can be a potentially effective and well-tolerated therapeutic modality in the treatment of nail psoriasis with comparable efficacy to intralesional injection.
Acanthosis nigricans is a common pigmentary disorder characterized by hyperpigmented and hyperkeratotic velvety skin lesions that presents mainly on the flexural sites, for example, the neck, the axillae, and groin. 1 The pathogenesis is mostly attributed to increased insulin resistance and hyperinsulinemia that result in stimulation of insulin growth factor 1 (IGF-1) receptors on keratinocytes and fibroblasts, leading to cellular proliferation. The dark color of AN is mostly due to hyperkeratosis rather than an increase in melanocytes. 2 It can be simply classified into four types: benign, malignant, drug-induced, and syndromic/pseudo-acanthosis nigricans. The term pseudo-acanthosis nigricans was referred to obese individuals who have AN with no underlying endocrinopathies. In these cases, the etiology was attributed to obesity, excessive local friction, and sweat. 3 The goal of therapy in AN is to correct the underlying disorder and treatment of AN lesions through cosmetic correction of the pigmentation. 4 Several topical and systemic agents have been used in the treatment of AN, for example, tretinoin, salicylic acid,
The term dilated facial pores refers to the visible openings on the surface of the skin that correspond to the dilated openings of pilosebaceous follicles. Large facial pores represent a common aesthetic complaint in both men and women with negative psychological impact. 1 They have been discussed in literature as sequelae of chronological aging and photoaging due to the defect in the collagen and elastin dermal framework. However, an increasing number of young patients are presenting at dermatology clinics with the complaint of dilated pores without signs of skin aging. 2 Other potential causative factors include sex, ethnic, and genetic predisposition, follicular size, and seborrhea. The association between increased sebum output and wide pores has been well established, and acne patients often complain of wide facial pores. 3 The treatment of dilated pores is difficult due to the multifactorial nature of its pathogenesis, and most current treatment options intend to address the associated factors. 4 A variety of treatment modalities have been tried, for example, topical and oral retinoids, chemical peels, microbotox, and energy-based devices. 4,5 The treatment
Background Recently, the interleukin-17A ( IL-17A) gene has emerged as a potential candidate gene for autoimmune disorders, including systemic lupus erythematosus (SLE). Objectives This study aimed to investigate whether IL-17A polymorphisms at rs2275913 G/A, rs8193036 C/T and rs3748067 C/T could be susceptibility markers for juvenile-onset SLE (JSLE) and lupus nephritis (LN) in Egyptian children and adolescents. Methods In this multi-centre study, we genotyped 320 patients diagnosed with JSLE and 320 matched control children for three IL-17A polymorphisms at rs2275913 G/A, rs8193036 C/T and rs3748067 C/T using TaqMan probe-based real-time polymerase chain reaction. Meanwhile, IL-17A serum levels were assessed using ELISA. Results The IL-17 rs2275913 A/A genotype and A allele were more represented in JSLE patients compared to the control group (21% vs. 7%, odds ratio (OR) = 3.8, 95% confidence interval (CI) 1.78–5.5, p = 0.001, pBonf = 0.003 for the A/A genotype; 37% vs. 29%, OR = 1.4, 95% CI 1.11–1.8, p = 0.003, pBonf = 0.009 for the A allele. No significant difference was found for IL-17 rs8193036 and rs3748067 single nucleotide polymorphisms (SNPs) in genotype distribution or allele frequencies ( p>0.05). Patients carrying the IL-17 rs2275913 A/A genotype and A allele were more likely to develop LN (OR = 5.64, 95% CI 2.39–13.77, pBonf = 0.001 for the A/A genotype; OR = 2.73, 95% CI 1.84–4.07, pBonf = 0.02 for the A allele). Conclusion The IL-17 rs2275913 A allele and A/A genotype were associated with high IL-17 serum levels and may contribute to susceptibility to JSLE and the development of LN in Egyptian children and adolescents. However, no significant association was evident between the studied IL-17A SNPs and other clinical phenotypes, disease activity scores or laboratory profile of JSLE.
Common warts present as hyperkeratotic, skin-colored papules located mainly on the dorsa of the hands and feet. The most prevalent genotypes of low-risk Human Papilloma virus (HPV) that cause cutaneous warts are HPV 1, 2, 3, 4, 10, 27, and 57, and from these genotypes 1, 2, 4, 27, and 57 cause common warts. 1 Most of the current therapeutic modalities depend on the ablation of warts. These include, among others, chemical cautery, electrocautery, cryotherapy, and laser therapy. This approach might be suitable for patients presenting with single or few lesions. In multiple warts, destructive procedures are inappropriate, impractical and might be associated with high rates of recurrence and significant adverse effects as pain, tissue destruction, infection, and scarring. 2
Background Pediatric-onset SLE (pSLE) is a multisystem autoimmune disease. Recently, the ficolin-2 (FCN2) gene has emerged as a potential candidate gene for susceptibility to SLE. Objectives The objective of this study was to evaluate the association of the FCN2 gene polymorphisms at positions −986 (G/A), −602 (G/A), −4 (A/G) and SNP C/T (rs3124954) located in intron 1, with susceptibility to pSLE in Egyptian children and adolescents. Methods This was a multicenter study of 280 patients diagnosed with pSLE, and 280 well-matched healthy controls. The FCN2 promoter polymorphisms at –986 G/A (rs3124952), −602 G/A (rs3124953), −4 A/G (rs17514136) and SNP C/T (rs3124954) located in intron 1 were genotyped by polymerase chain reaction, while serum ficolin-2 levels were assessed using enzyme-linked immunosorbent assay. Results The frequencies of the FCN2 GG genotype and G allele at −986 and −602 positions were significantly more represented in patients with pSLE than in controls ( p < 0.001). Conversely, the FCN2 AA genotype and A allele at position −4 were more common in patients than in controls ( p < 0.001). Moreover, patients carrying the FCN2 GG genotype in −986 position were more likely to develop lupus nephritis (odds ratio: 2.6 (95% confidence interval: 1.4–4.78); p = 0.006). The FCN2 AA genotype at position −4 was also identified as a possible risk factor for lupus nephritis (odds ratio: 3.12 (95% confidence interval: 1.25–7.84); p = 0.024). Conclusion The FCN2 promoter polymorphisms may contribute to susceptibility to pSLE in Egyptian children and adolescents. Moreover, the FCN2 GG genotype at position −986 and AA genotype at position −4 were associated with low serum ficolin-2 levels and may constitute risk factors for lupus nephritis in pSLE.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.